A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma
LEAD IN: Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1.
Treatment repeats every 21 days for 2 courses in the absence of disease progression or
AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and
dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6
courses in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day
1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or
After completion of study treatment, patients are followed up at 30 days.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate after chemotherapy
The primary objective of this study is to assess the overall response rate among older patients with HL receiving sequential brentuximab vedotin therapy with AVD chemotherapy
United States: Institutional Review Board
|MD Anderson Cancer Center||Houston, Texas 77030-4096|
|Stanford University Medical Center||Stanford, California 94305-5408|
|University of Massachusetts Medical School||Worcester, Massachusetts 01605|
|University of Chicago||Chicago, Illinois 60637|
|NorthwesternU||Chicago, Illinois 60611|
|Memorial Sloan- Kettering Cancer Center||New York, New York 10065|